Toronto Maple Leafs prospect Rodion Amirov has died less than 2 years since being diagnosed with a brain tumor. He was 21.

Agent Dan Milstein confirmed to The Associated Press that Amirov died Monday in Munich, Germany. The team said in February 2022 that Amirov had a brain tumor and would go to Germany for treatment, in the hopes of being able to resume his hockey career at some point.

“From the moment he received the news, he refused to speak in the negative, determined to enjoy every day, facing it with the same positive attitude he showed during his hockey career,” Milstein said in a message posted on social media in English and Russian. “We will always remember his courage, his desire, his will, his smile – all of the great things about him.”

Milstein also thanked the doctors who took care of Amirov, as well as the Maple Leafs and Kontinental Hockey League’s Salavat Yulayev Ufa, who “did everything possible to help in any way.”

BRUINS: David Krejci announces retirement

The Maple Leafs said their organization was devastated by the news of Amirov’s death.

“Over the duration of his courageous battle, Rodin’s positively inspired everyone around him and made lasting impressions with our team and fans in his brief visits to Toronto,” team president Brendan Shanahan said. “It’s incredibly sad to see a young man with so much promise taken from us so soon.”

Toronto selected Amirov with the 15th pick in the 2020 NHL draft. The Salavat, Russia, native was playing in the KHL with his hometown team in 2021 before being sidelined by an injury 10 games into the season.

Then-general manager Kyle Dubas said Amirov developed unrelated symptoms over the course of his recovery that required “ongoing extensive investigations.” Amirov went to Toronto for four rounds of chemotherapy last fall and received an ovation at a Maple Leafs game against Washington on Oct. 14.

Disclaimer: The copyright of this article belongs to the original author. Reposting this article is solely for the purpose of information dissemination and does not constitute any investment advice. If there is any infringement, please contact us immediately. We will make corrections or deletions as necessary. Thank you.